While CML treatment at physiological concentrations significantly upregulated glycation markers (RAGE and AGER1), it did not affect bone remodeling markers or inflammatory cytokines, nor did it alter cell viability or apoptosis. Here, AGER is linked to chronic myelogenous leukemia, BCR-ABL1 positive.